GLP-1 drugs like Wegovy and Zepbound have been racking up sales and new indications, as researchers learn more about how the ...

An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression ...

Scientists have failed to show that weight-loss wonder drug semaglutide slows the progress of Alzheimer's disease (AD), as ...

The biomarker improvements in the EVOKE studies are worth noting, observed Howard Fillit, MD, of the Alzheimer's Drug ...

Novo Nordisk today announced the top-line results from the 2-year primary analysis of evoke and evoke+ phase 3 trials in ...

Scientists have uncovered a surprising mechanism by which a brain enzyme called OTULIN controls the expression of tau, the ...

An oral version of the GLP-1 drug semaglutide failed to significantly slow the disease's progression compared to a placebo.

Rutgers neuroscientist Peng Jiang and his neuroscience colleague Mengmeng Jin have made a discovery they say could reshape ...

But perhaps the larger story associated with the unsurprising result is the market reaction, as Novo's shares fell by nearly 9% at the U.S. market open Monday.

In people at risk for Alzheimer’s disease, researchers linked minimal to moderate physical activity to a 3-to 7-year delay in cognitive symptoms.

Other noteworthy news in Alzheimer's disease this year included: News about Alzheimer's rose to the forefront in 2025, as the ...

Shares of Biogen rose 3% following news of Novo's Alzheimer's trial failure. Biogen and partner Eisai's Leqembi and rival Eli ...